Compare RDY & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDY | IVZ |
|---|---|---|
| Founded | 1984 | 1935 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 13.1B |
| IPO Year | N/A | 1995 |
| Metric | RDY | IVZ |
|---|---|---|
| Price | $13.85 | $27.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 15 |
| Target Price | $16.90 | ★ $27.43 |
| AVG Volume (30 Days) | 1.8M | ★ 6.5M |
| Earning Date | 01-20-2026 | 01-27-2026 |
| Dividend Yield | 0.53% | ★ 3.06% |
| EPS Growth | ★ 5.58 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | $3,848,694,754.00 | ★ $6,377,100,000.00 |
| Revenue This Year | $6.12 | N/A |
| Revenue Next Year | $2.58 | $4.62 |
| P/E Ratio | $17.93 | ★ N/A |
| Revenue Growth | ★ 11.09 | 5.11 |
| 52 Week Low | $12.26 | $11.60 |
| 52 Week High | $16.17 | $29.61 |
| Indicator | RDY | IVZ |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 44.39 |
| Support Level | $12.95 | $26.77 |
| Resistance Level | $13.85 | $28.23 |
| Average True Range (ATR) | 0.27 | 0.97 |
| MACD | 0.05 | -0.29 |
| Stochastic Oscillator | 91.20 | 13.55 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients. At the end of November 2025, the firm had $2.154 trillion in assets under management spread among its equity (62% of AUM), balanced (3%), fixed-income (20%), alternative investment (6%), and money market (9%) operations. Passive products account for close to half of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 31% of its AUM sourced from Europe, Africa, and the Middle East (16%) and Asia (15%).